REG - Morgan Stanley Cap - Rule 38.5 - ABBVIE INC.

Morgan StanleyAnnouncement

04/03/2020 11:45

RNS Number : 9949E
  
Morgan Stanley Capital Services LLC
  
04 March 2020
  
 

 
 FORM 38.5 
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)
 
DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS
 
1.             KEY INFORMATION



 Name of exempt market-maker


   Morgan Stanley Capital Services LLC




 Company dealt in


   ABBVIE INC.




 Class of relevant security to which the dealings being disclosed relate (Note 1)


  US$0.01 COMMON STOCK




 Date of dealing


   03 MARCH 2020



 
 
2.             DEALINGS (Note 2)
 
(a)           Purchases and sales



 Total number of relevant secuities accquired


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  31,721


 90.5600 USD


 85.6600 USD



 



 Total number of relevant secuities disposed


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  61,241


 90.1100 USD


 85.9350 USD



 
 
(b)           Derivatives transactions (other than options transactions)
 



 Product name, e.g. CFD


 Nature of transaction 
                (Note 4)


 Number of relevant securities 
                (Note 5)


 Price per unit




 CFD


 LONG


 8,463


 86.1059 USD




 CFD


 LONG


 197


 86.1059 USD




 CFD


 LONG


 4,200


 87.4400 USD




 CFD


 LONG


 4,229


 87.5021 USD




 CFD


 LONG


 6


 87.5700 USD




 CFD


 LONG


 1,600


 87.5700 USD




 CFD


 LONG


 4,800


 87.7376 USD




 CFD


 LONG


 200


 87.7376 USD




 CFD


 LONG


 1,300


 87.7376 USD




 CFD


 LONG


 200


 87.7376 USD




 CFD


 LONG


 400


 87.7376 USD




 CFD


 LONG


 1,300


 87.7376 USD




 CFD


 LONG


 2,600


 87.7376 USD




 CFD


 LONG


 2,800


 87.7376 USD




 CFD


 LONG


 6,442


 88.4792 USD




 CFD


 LONG


 258


 88.4792 USD




 CFD


 LONG


 1,019


 89.2399 USD




 CFD


 LONG


 1,315


 89.2399 USD




 CFD


 LONG


 45


 89.2400 USD




 CFD


 LONG


 1,000


 89.4020 USD




 CFD


 SHORT


 66


 87.3200 USD




 CFD


 SHORT


 56


 87.5700 USD




 CFD


 SHORT


 1,406


 88.1069 USD




 CFD


 SHORT


 66


 88.1700 USD




 CFD


 SHORT


 5,509


 88.2045 USD




 CFD


 SHORT


 1,030


 88.2692 USD




 CFD


 SHORT


 600


 88.4583 USD




 CFD


 SHORT


 259


 88.6375 USD




 CFD


 SHORT


 39


 88.6375 USD




 CFD


 SHORT


 290


 90.0556 USD



 
 
(c)            Options transactions in respect of existing relevant securities
 
i)           Writing, selling, purchasing or varying
 



 Product name, eg call option


 Writing, selling, purchasing, varying etc


 Number of securities to which the option relates (Note 5)


 Exercise Price


 Type, e.g American, European etc 


 Expiry Date 


 Option money paid/received per unit (Note 3)




 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A 



 
(ii) Exercising
 



 Product name, eg call option


 Number of securities


 Exercise price per unit (Note 3)




 N/A


 N/A


 N/A  



 
 
3. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 



Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 




 
 
 
 
 



 
 



 Date of disclosure


 04 MARCH 2020




 Contact Name


Craig Horsley




 Telephone Number


+44(141) 245 7736 




 Name of offeree/offeror with which connected


ABBVIE INC. 




Nature of connection (Note 6)


Advisory 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEUSSRRRUUORAR